Oxazoloisoquinoline derivatives as thrombin receptor antagonists
    93.
    发明申请
    Oxazoloisoquinoline derivatives as thrombin receptor antagonists 有权
    恶唑啉异喹啉衍生物作为凝血酶受体拮抗剂

    公开(公告)号:US20070149518A1

    公开(公告)日:2007-06-28

    申请号:US11642170

    申请日:2006-12-20

    CPC分类号: C07D487/04 C07D471/04

    摘要: Heterocyclic-substituted bi or tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein An, Mn, Un, Gn, Jn, Kn, R9, R10, R11, R32, R33, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

    摘要翻译: 异构体或外消旋混合物的式I化合物或其药学上可接受的盐或溶剂化物,其中表示可选的双键,虚线是可选的键或无键,导致 双键或单键,如价格要求所允许的,并且其中A是N,N,N, N,N,N,R 9,R 10,R 11, 本文中定义了11,32,R 32,R 33,B和Het,并且其余取代基如说明书中所定义,以及药物 含有它们的组合物和治疗与血栓形成,动脉粥样硬化,再狭窄,高血压,心绞痛,心律失常,心力衰竭和消除相关的疾病的方法 通过施用所述化合物。 还要求与其它心血管药物联合治疗。

    Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
    94.
    发明申请
    Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists 有权
    吡唑并[4,3-e] -1,2,4-三唑并 - [1,5-c] - 嘧啶腺苷A2a受体拮抗剂

    公开(公告)号:US20050239795A1

    公开(公告)日:2005-10-27

    申请号:US11108916

    申请日:2005-04-19

    IPC分类号: A61K31/519 C07D487/14

    CPC分类号: C07D487/14

    摘要: Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

    摘要翻译: 具有结构式I的化合物或其药学上可接受的盐,其中R是任选取代的苯基,呋喃基,噻吩基,吡啶基,吡啶基N-氧化物,恶唑基或吡咯基,或环烯基R 1, R 3,R 3,R 4和R 5是H,烷基或烷氧基烷基; 和Z是任选取代的芳基或杂芳基。 还公开了式I化合物在治疗中枢神经系统疾病,特别是帕金森病中单独使用或与用于治疗帕金森病的其它药物组合的用途,以及包含它们的药物组合物的用途。

    Ether muscarinic antagonists
    98.
    发明授权
    Ether muscarinic antagonists 失效
    醚类毒蕈碱拮抗剂

    公开(公告)号:US5977138A

    公开(公告)日:1999-11-02

    申请号:US910616

    申请日:1997-08-13

    摘要: 1,4 Di-substituted piperidine muscarinic antagonists of formula I ##STR1## or an isomer, pharmaceutically acceptable salt, ester or solvate thereof, whereinX is a bond, --O--, --S--, --SO--, --SO.sub.2 --, --CO--, --C(OR.sup.7).sub.2 --, --CH.sub.2 --O--, --O-- CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 --, --CH(C.sub.1 -C.sub.6 alkyl)-, --C(C.sub.1 -C.sub.6 alkyl).sub.2 --, --CONR.sup.17 --, --NR.sup.17 CO--, --O--C(O)NR.sup.17 --, --NR.sup.17 C(O)--O--, --SO.sub.2 NR.sup.17 -- or --NR.sup.17 SO.sub.2 --;R is cycloalkyl, optionally substituted phenyl or optionally substituted pyridyl;R.sup.2 is H, alkyl, optionally substituted cycloalkyl, cycloalkenyl, t-butoxycarbonyl or optionally substituted piperidinyl; and the remaining variables are as defined in the specification, are disclosed. Compounds of formula I are useful for treating cognitive disorders such as Alzheimer's disease. Also disclosed are pharmaceutical compositions, methods of preparation and combinations of compounds of formula I with ACh'ase inhibitors.

    摘要翻译: 1,4-二取代的式I的哌啶毒蕈碱拮抗剂或其异构体,药学上可接受的盐,酯或溶剂化物,其中X是键,-O - , - S - , - SO - , - SO 2 - , - ,-C(OR 7)2 - , - CH 2 -O - , - CH 2 - , - CH = CH - , - CH 2 - , - CH(C 1 -C 6烷基) - , - CONR 17 - , - NR 17 CO - , - OC(O)NR 17 - , - NR 17 C(O)-O-,-SO 2 NR 17 - 或-NR 17 SO 2 - R是环烷基,任选取代的苯基或任选取代的吡啶基; R2是H,烷基,任选取代的环烷基,环烯基,叔丁氧羰基或任选取代的哌啶基; 并且其余变量如说明书中所定义。 式I化合物可用于治疗认知障碍如阿尔茨海默病。 还公开了药物组合物,制备方法和式I化合物与ACh酶抑制剂的组合。

    4-substituted pyrazoloquinoline derivatives
    100.
    发明授权
    4-substituted pyrazoloquinoline derivatives 失效
    4-取代的吡唑并喹啉衍生物

    公开(公告)号:US5608067A

    公开(公告)日:1997-03-04

    申请号:US234695

    申请日:1994-04-28

    IPC分类号: C07D471/04

    CPC分类号: C07D471/04

    摘要: Disclosed herein are compounds of the formula ##STR1## wherein R.sub.1, R.sub.3, R.sub.4, R.sub.11, and c are as set forth herein are described. These compounds are useful as agents for the treatment of mammals infected with herpes group virus. Certain of these compounds are useful as antitumor agents.

    摘要翻译: 本文公开的是其中R 1,R 3,R 4,R 11和c如本文所述的式Ⅺ的化合物。 这些化合物可用作治疗感染疱疹病毒的哺乳动物的药剂。 这些化合物中的某些可用作抗肿瘤剂。